Welcome to the e-CCO Library!

P341: Combination of corticosteroids and 5-aminosalycilates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: a global survey of physicians' practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ben-Horin S.*1,2, Andrews J.M.3, Katsanos K.H.4, Rieder F.5, Steinwurz F.6, Karmiris K.7, Cheon J.H.8, Moran G.W.9, Cesarini M.10, Stone C.D.11, Schwartz D.12, Protic M.13, Roblin X.14, Roda G.15, Chen M.2, Har-Noy O.1, Bernstein C.N.16

Created: Wednesday, 20 February 2019, 10:36 AM
P341: Faecal biomarkers compared with MRI using the MaRIA and Clermont scores for monitoring inflammatory activity in patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Langhorst1*, A. Koch1, J. Boone2, A. Rueffer3, G. Dobos4, L. Umutlu5, Y. Li5

Created: Thursday, 21 February 2019, 9:14 AM
P341: Fracture risk in middle-age and older patients with inflammatory bowel disease: A Korean nationwide population-based cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ji Min, L.(1)*;Lee, K.M.(2);Han, K.D.(3);
Created: Friday, 14 July 2023, 11:05 AM
P341: Identification and management of psychological distress after stoma surgery: a qualitative study of patients and healthcare professionals
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Polidano*1, C. A. Chew-Graham1,2,3, A. D. Farmer4,5, B. Saunders1

Created: Friday, 22 February 2019, 9:41 AM
P341: Perceived risks and psychosocial burden during the COVID-19 pandemic in a large cohort of pediatric and adult patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Koletzko, L.(1);Klucker, E.(2);Le Thi, G.(2);Breiteneicher, S.(1);Rubio-Acero, R.(3);Neuhaus, L.(1);Stark, R.(4);Standl, M.(5);Hölscher, M.(3);Török, H.(1);Koletzko, S.(2,6);Schwerd, T.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P341: Pharmacokinetics and exposure-response analyses of upadacitinib in patients with moderate to severe ulcerative colitis – Analyses of induction and maintenance clinical trials
Year: 2022
Source: ECCO'22
Authors: Ponce-Bobadilla, A.V.(1);Stodtmann, S.(1);Eckert, D.(1);Zhou, W.(2);Liu, W.(2);Mohamed, M.E.(2);
Created: Friday, 11 February 2022, 3:52 PM
P342 Diagnostic accuracy of rectal bleeding and stool frequency in predicting mucosal healing in patients with ulcerative colitis in the tofacitinib OCTAVE Phase 3 induction studies
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.F. Colombel1, A.G. Bushmakin2, J.C. Cappelleri2, N. Kulisek3, G.O. Santana4, N. Lawendy3, D. Ponce de Leon5, P.L. Lakatos6

Created: Thursday, 30 January 2020, 10:12 AM
P342: A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Dreesen*1, B. Verstockt2,3, S. Vermeire2,3, M. Ferrante2,3, A. Gils1

Created: Friday, 22 February 2019, 9:41 AM
P342: Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique
Year: 2021
Source: ECCO'21 Virtual
Authors: Ruiz-Argüello, M.B.(1);Pascual, J.(1);Del Río, L.(1);Urigoitia, A.(1);Balo Farto, C.(2);Fernández, C.(3);Mera, A.(2);De Toro, J.(3);Nagore, D.(1);Ametzazurra, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P342: Development of self-screening tool for perianal disease in patients with Crohn’s disease: A pilot study
Year: 2018
Source: ECCO '18 Vienna
Authors:

E.S. Kim1, B.I. Jang2*, H.S. Lee1, Y.J. Lee3, E.Y. Kim4, K.O. Kim2, K.H. Song5, S.K. Kim1, Crohn's and Colitis Association in Daegu-Gyeongbuk (CCAiD)

Created: Thursday, 21 February 2019, 9:14 AM
P342: Maladaptive coping, self-efficacy and patient reported outcomes in inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Chao C.-Y.*1,2, Lemieux C.1, Afif W.1, Bitton A.1, Wild G.1, Bessissow T.1

Created: Wednesday, 20 February 2019, 10:36 AM
P342: Trans-continental analysis of over 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium
Year: 2022
Source: ECCO'22
Authors: Wong, S.Y.(1);Helmus, D.(2);Marlow, L.(3);Martinez Pazos, V.(2);Brann, S.(3);Wellens, J.(4);Kedia, S.(5);Mak , J.W.Y.(6);Bergemalm, D.(7);Argollo, M.(8);Zaltman, C.(9);Steinwurz, F.(10);Rubin, D.(11);Allez, M.(12);Halfvarson, J.(7);Abreu, M.T.(13);Lindsay, J.(14);Dutta, U.(15);Silverberg, M.S.(16);Ng, S.C.(6);Ahuja, V.(5);Watanabe, K.(17);Vermeire, S.(18);Colombel, J.F.(2);Satsangi, J.(19);
Created: Friday, 11 February 2022, 3:52 PM
P342: Treatment experience of perianal fistulising Crohn's disease: a systematic literature review
Year: 2023
Source: ECCO’23 Copenhagen
Authors: McKay, C.(1)*;Pacis, S.(2);Bolzani, A.(2);Geransar, P.(3);Panés, J.(4);
Created: Friday, 14 July 2023, 11:05 AM
P342: Tryptophan as a biomarker for the course of IBD and anti-TNF α response
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Brandt*1, S. Nikolaus2, N. Al-Massad2, J. Bethge2, D. Schuldt2, S. Szymczak3, F. Thieme4, G. H. Waetzig5, M. Krawczak3, R. Junker4, P. Rosenstiel6, S. Schreiber2

Created: Friday, 22 February 2019, 9:49 AM
P343 Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. Akyüz, A. Ormeci, N. Namazova, M. Guzel, A. Abbasgoulizadeh, L. Tahincioğlu, S. Alaskarlı, E. Gürel, E. Bilgin, A. Atasoy, B. Cavus, K. Demir, F. Besısık, S. Kaymakoğlu

Created: Thursday, 30 January 2020, 10:12 AM
P343: Changing the coUrse of cRohn’s disease with an Early use of adalimumab: The CURE study from the GETAID
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Bouhnik, Y.(2);Laharie, D.(3);Elgharabawy, Y.(4);
Created: Friday, 11 February 2022, 3:52 PM
P343: Efficacy of ustekinumab in Crohn’s disease at maintenance Week 56: IM-UNITI study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

W. J. Sandborn*1, B. Sands2, J-F. Colombel2, C. Gasink3, R. Patel4, D. Jacobstein5, L-L. Gao5, S. Ghosh6, S. Targan7, W. De Villiers8, S. B. Hanauer9, P. Rutgeerts10, B. Feagan11

Created: Friday, 22 February 2019, 9:41 AM
P343: Eosinophilic inflammation as an indicator of the activity of the course of Inflammatory Bowel Diseases
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Babayeva-Sadigova, G.(1)*;Asadova, G.(2);Quliyev , F.(2);Makhmudov , U.(3);Ismayilova , K.(1);Samedova , T.(2);Hasanova , A.(4);Mirzazada , O.(4);Mahammadaliyeva , M.(4);Abdulzada , C.(4);Musayev, C.(5);Iskenderov , N.(6);
Created: Friday, 14 July 2023, 11:05 AM
P343: Female gender, somatization and presence of IBS-type symptoms predicts Dyspareunia in patients with IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

O'Connor A.*1, Gracie D.1, Hamlin J.1, Selinger C.1, Ford A.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P343: Levels of the anticoagulant and anti-inflammatory protein S (PROS1) in patients with inflammatory bowel disease (IBD) relationship with disease activity, IBD disease patterns, and C4-binding protein (C4BP)
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Sambuelli1*, P. Chavero1, G. de Larrañaga2, A. Errasti3, S. Peres2, L. Tessone3, S. Negreira2, N. Silvia1, M. Bellicoso1, S. Huernos1, S. Goncalves1, P. Tirado1, E.A. Carrera Silva4, C. Rothlin5

Created: Thursday, 21 February 2019, 9:14 AM